Welcome to Multibagg AI
Log in to access personalized features
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stockBearish
2
Neutral
7
Bullish
5
Bearish
9
Neutral
7
Bullish
30
Bearish
7
Neutral
0
Bullish
25
Bearish
2
Neutral
7
Bullish
5
Bearish
2
Neutral
7
Bullish
5
Bearish
7
Neutral
0
Bullish
25
Bearish
7
Neutral
0
Bullish
25
Bearish
7
Neutral
0
Bullish
25
Ind-Swift Laboratories Ltd is a pharmaceutical manufacturer repositioned as a pure‑play Finished Dosage Formulations (FDF) company focused on exports, contract manufacturing (CDMO/CMO) and domestic branded/ethical therapies, operating two accredited manufacturing sites (Derabassi EOU and Samba) and an R&D centre supporting regulated‑market dossiers and tech transfers.
The company completed a strategic reset by divesting its capital‑intensive API & CRAMS business for ₹1,650 Cr, repaying all external debt and emerging as a net‑debt‑free formulations platform with a retained 7.8% stake in the buyer, materially improving balance sheet flexibility for growth investments.
Commercialisation with Viatris and other long‑term CMO partners is a key growth catalyst: Ind‑Swift expects commercial supplies to Viatris to begin FY27 and to contribute roughly ₹200–220 Cr incremental revenue, materially accelerating the Global Business Unit and CDMO revenue trajectory.
Ind‑Swift has a deep dossier and approvals footprint—1,915+ dossiers filed and 520+ global approvals—combined with Derabassi capacity capable of supporting >₹10 billion revenue, giving the company visibility to scale exports, launch 400+ new registrations by 2026, and pursue regulated‑market launches and out‑licensing opportunities.
Near‑term financial momentum shows stable quarterly revenues (~₹177 Cr Q3 FY26 total revenue) with improving operating EBITDA margins (5.95% Q3 FY26) and sequential PAT growth of 22.6% quarter‑on‑quarter, reflecting cost efficiencies and non‑operating income variability amid the post‑transformation phase.
Pharmaceuticals & Biotechnology
Pharmaceuticals
3,245 Cr
Low Risk
56.7
37.5
-0.6
2.3
403.00
87.00
Sales CAGR
Profit CAGR
ROE
ROCE
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Investor Presentation
Q1 FY27
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Investor Presentation
Q2 FY21
Investor Presentation
Q1 FY21
Ind-Swift Laboratories Ltd (INDSWFTLAB) is currently trading at 374.15 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Ind-Swift Laboratories Ltd is a pharmaceutical manufacturer repositioned as a pure‑play Finished Dosage Formulations (FDF) company focused on exports, contract manufacturing (CDMO/CMO) and domestic branded/ethical therapies, operating two accredited manufacturing sites (Derabassi EOU and Samba) and an R&D centre supporting regulated‑market dossiers and tech transfers. The company completed a strategic reset by divesting its capital‑intensive API & CRAMS business for ₹1,650 Cr, repaying all external debt and emerging as a net‑debt‑free formulations platform with a retained 7.8% stake in the buyer, materially improving balance sheet flexibility for growth investments. Commercialisation with Viatris and other long‑term CMO partners is a key growth catalyst: Ind‑Swift expects commercial supplies to Viatris to begin FY27 and to contribute roughly ₹200–220 Cr incremental revenue, materially accelerating the Global Business Unit and CDMO revenue trajectory. Ind‑Swift has a deep dossier and approvals footprint—1,915+ dossiers filed and 520+ global approvals—combined with Derabassi capacity capable of supporting >₹10 billion revenue, giving the company visibility to scale exports, launch 400+ new registrations by 2026, and pursue regulated‑market launches and out‑licensing opportunities. Near‑term financial momentum shows stable quarterly revenues (~₹177 Cr Q3 FY26 total revenue) with improving operating EBITDA margins (5.95% Q3 FY26) and sequential PAT growth of 22.6% quarter‑on‑quarter, reflecting cost efficiencies and non‑operating income variability amid the post‑transformation phase.
Over the past 52 weeks, Ind-Swift Laboratories Ltd has traded between a low of ₹87.00 and a high of ₹403.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Ind-Swift Laboratories Ltd has a market capitalization of approximately 3,244.54. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Ind-Swift Laboratories Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 56.68 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 3,244.54 Cr, Ind-Swift Laboratories Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Ind-Swift Laboratories Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Ind-Swift Laboratories Ltd is 56.68. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Standalone PAT excluding exceptional items was ₹24.68 crore in Q1 FY27, up 2.04 times year-on-year from ₹8.12 crore in Q1 FY26.
Standalone PAT excluding exceptional items was ₹24.68 crore in Q1 FY27, up 2.04 times year-on-year from ₹8.12 crore.
The company declared its Q1 FY27 results on August 10, 2026 for the quarter ended June 30, 2026.
Shareholders passed three special resolutions: issuance of up to 70,00,000 fully convertible warrants to a promoter group entity, reappointment of an independent director, and substitution of Article 76 in the AoA.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
545.25 | 3,841 Cr | 12.60 | 1.41 | 0.00 | 2.88 | 3.79 | 8.15 | ||
3469.95 | 3,606 Cr | 44.49 | 10.90 | 0.00 | 20.31 | 21.46 | 13.69 | ||
743.00 | 3,595 Cr | -2219.30 | 2.86 | 0.00 | -0.12 | 4.81 | -0.07 | ||
374.15 | 3,245 Cr | 56.68 | 2.34 | 0.00 | 3.57 | 4.36 | 3.42 | ||
228.95 | 2,788 Cr | -82.48 | 2.33 | 0.27 | 3.03 | 3.56 | -1.43 | ||
170.45 | 2,672 Cr | 165.37 | 0.40 | 0.00 | 1.46 | 2.66 | 0.14 | ||
1179.80 | 2,625 Cr | 72.74 | 8.09 | 0.00 | 9.40 | 12.54 | 7.50 | ||
| Median: 7 Co. | — | 545.25 | 3,245 Cr | 44.49 | 2.34 | 0.00 | 3.03 | 4.36 | 3.42 |
